InvestorsHub Logo
Followers 17
Posts 936
Boards Moderated 0
Alias Born 04/26/2010

Re: frrol post# 230835

Friday, 06/15/2018 3:02:49 PM

Friday, June 15, 2018 3:02:49 PM

Post# of 403074
Thanks ffrol. I guess my DD skill needs some improving. Yes, I have sent few emails to Leo about P results - silence. But then, I am not reputable investor :)
I hope you are correct about B negotiation whatever the schedule.
About K: it may be off hold sooner than some people think. Aprea's ovarian cancer studies have primary completion dates Sep-2018 and Nov-2018. If Aprea succeeds with APR-246 then one well designed P1/2 trial showing that Kevetrin does indeed activate p53 in human should generate plenty of mee-too interest.

"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News